Missouri Senate committee considers reverse-switch of PSE
JEFFERSON CITY, Mo. A Missouri Senate committee on Monday entertained legislation that would mandate the reverse-switch of all products containing ephedrine, pseudoephedrine or phenylpropanolamine — all products currently sold and tracked from behind the pharmacy counter per the Combat Meth Act.
The bill would exempt dietary supplements containing naturally-occurring ephedrine alkaloids that constituted less than 15% of the total weight of the supplements; however, supplements containing ephedrine have been banned from sale by the Food and Drug Administration since 2004. PSE and PPA are drugs, and therefore cannot be legally sold as supplements. PPA is also no longer available for sale OTC — the FDA requested that PPA products be pulled from the market in 2000.
That leaves only PSE products that are currently available in drug stores, and if the legislation passes this year, PSE products will become prescription-only drugs througout the state.
The move would limit access to PSE, critics charge, and would force consumers with nothing more than a common cold out of their local drug stores and into their local doctor’s offices.
Oregon switched PSE to prescription-only in 2006, and have since claimed that the move has nearly eliminated methamphetamine labs.
Part of the impetus behind the bill may be financial. The state has yet to release funds to support electronic logbook requirements on the sale of PSE, according to published reports, and switching PSE to prescription-only status would relieve the legislature from that financial burden.
World Research Group to host mobile-phone diabetes seminar
NEW YORK World Research Group announced Wednesday that it will be host to a Web-based seminar on improving diabetes management through mobile phone technology.
The agenda will include discussions on how mobile technology can improve disease management; key factors in selecting and enrolling patients, increasing adherence to medical regimens and supporting provider workflow; how mobile technology facilitates improved patient and provider interaction; and improvements in patient adherence, blood-glucose control and patient satisfaction.
Woodward Labs launches at-home nail fungus screening kit
ALISO VIEJO, Calif. Woodward Laboratories on Tuesday launched the Mycocide Nail Fungus Test Kit, the first at-home screening kit that helps diagnose toe and finger nail fungus.
“People think nail fungus is simply cosmetic, so they ignore going to the doctor to have it checked,” stated Ken Gerenraich, CEO of Woodward Laboratories. “However, nails are a window to a person’s health and if nail fungus goes undiagnosed, there can be significant health issues — especially for diabetics. The Mycocide Nail Fungus Test Kit allows people to diagnose the presence of nail fungus without spending money on co-payments, lab fees and doctors and they can do it in the comfort and privacy of their own home.”
The Mycocide Nail Fungus Test Kit provides patients with a convenient, less expensive and confidential way to determine in the comfort of their own home if they have nail fungus. Consumers use the provided nail clipper to collect a sample of a discolored and possibly infected nail and mail it to Woodward Laboratories in a postage pre-paid envelope. The nail is tested and a podiatric medical doctor reads and certifies the diagnosis. Results are mailed back to the consumer and if the test is positive, clients receive a coupon for Woodward Laboratories’ Mycocide NS, an over-the-counter antifungal treatment. Suggested retail price for the Mycocide Nail Fungus Test Kit is $20.
As part of the product launch, Woodward Laboratories will offer 10,000 consumers a free test kit through its web site, www.IsItNailFungus.com.